CompanyATTONasdaqSan Carlos, CA

Attovia Therapeutics Inc

Attovia is a clinical-stage biopharmaceutical company developing biparatopic and multispecific biologics for immune-mediated diseases.

SEC EDGAR ClinicalTrials.gov attovia.com

10-QSep 2Latest SEC filing, period to Jun 30

Sep 22Latest story

September 2026

Attovia registers Phase 2 trial of ATTO-1310 for chronic pruritus of unknown origin

Sep 22Trial updateATTO-1310 Attovia Therapeutics Inc

Attovia registers Phase 1 trial of ATTO-1091 for ulcerative colitis

Sep 15Trial updateATTO-1091 Attovia Therapeutics Inc

Attovia reports ATTO-1310 pruritus proof of concept, plans Phase 2 for 2027

Sep 2Quarterly updateATTO-1310 Attovia Therapeutics Inc

August 2026

Attovia Therapeutics prices $289 million IPO ahead of Nasdaq debut

Aug 5FinancingAttovia Therapeutics Inc

July 2026

Attovia Therapeutics files S-1 for IPO on Nasdaq under ticker ATTO

Jul 14FinancingAttovia Therapeutics Inc